low-dose naltrexone for Interstitial Cystitis

"Low-dose naltrexone is usually used to manage chronic weight, but it can also be applied therapeutically to increase physical activity, reduce pain and support a reduced calorie diet."

"There is ample evidence that low-dose naltrexone has been approved for use, thus receiving a score of 3 on the safety scale."

"Indeed, the clinicaltrials.gov portal indicates that this research trial is actively collecting patients for their study. It was published on September 7th 2021 and last reviewed on April 4th 2022. In total, 44 subjects are needed from one site."

"The primary metric of this six-week clinical trial is the Visual Analogue Scale. Secondary outcomes encompass the Pelvic Pain and Urgency/Frequency Patient Symptom Scale (ranging from 0 to 23, with higher scores indicating more severe IC/PBS symptoms), a survey of patient Quality of Life via SF-36 (from 0 to 100, where better health status is indicated by greater values) as well as urinary frequency observed through 24 hour bladder diaries."

"This clinical trial seeks 44 participants aged 18 to 110 who suffer from bladder-related discomfort. In addition, candidates must have not been treated for the condition in the last four weeks, be able to communicate fluently in English and provide a blood sample for liver enzyme evaluation. Furthermore, they should have had cystoscopy within 6 months prior to study commencement and possess a functioning telephone number."

"Currently, there are 46 clinical trials centred around low-dose naltrexone. Of those studies, 12 have advanced to Phase 3. Despite the majority of these investigations being based in New york City, there are 161 different sites running related research globally."

"The boundaries for this trial are set at 18 to 110 years of age. For those outside the range, 454 studies are available for participants under 18 and 1284 clinical trials exist that cater to individuals aged 65 or older."

"Affirmative. Clinicaltrials.gov exhibits that this clinical trial is still enrolling participants, with the first post on September 7th 2021 and a recent update on April 4th 2022. The research team need to recruit 44 individuals from 1 medical facility."